Home » Biotech & Pharma » iBio (NYSEMKT:IBIO) Joins Hands With Caliber Biotherapeutics
iBio (NYSEMKT:IBIO) Joins Hands With Caliber Biotherapeutics
by Mike Rosenberg
November 18, 2014
Biotech & Pharma
iBio, Inc. (NYSEMKT:IBIO) and Caliber Biotherapeuticshave executed an agreement for an emergency useof theiBioLaunch™ platform for production of antibodies by Caliber that target the Ebola virus.
Collaborative Relationship of iBio and Caliber:
As announced previously on 15thJanuary and 16th October, 2014, iBio Inc. and Caliber Biotherapeuticshave had a collaborative relationship that is reflected by a License and Collaboration Agreement that was signed on 14th February, 2013. Both iBioInc. and Caliber Biotherapeuticshave been involved in examining how the companies could use their technologies and the facilities in assisting the governments to address the issue of Ebola epidemic since early September.
Other Collaborations of Two Companies:
iBio, Inc. (NYSEMKT:IBIO). and Caliber Biotherapeutics are also are collaborating on certain commercial opportunities for the recombinant antibodies and antibody-related proteins that could benefit from the efficiency, speed, and cost advantages of production of pharmaceutical proteins in plants rather than bioreactor-based manufacturing methods that use Chinese hamster ovary (CHO) cells.
License Expands Freedom of Caliber Biotherapeutics:
The license that has been announced expands the freedom of Caliber Biotherapeuticsto operate under the issued U.S. patents and related intellectual property of iBio Inc.that would enable Caliber in assisting the U.S. government by the manufacture of some experimental drugs that would address the Ebola virus outbreak. Caliber Biotherapeuticsoperates the world’s largest capacity cGMP manufacturing facility that is capable to use the technology of iBio, Inc. for the production of monoclonal antibodies, vaccines and other biotherapeutics.
More AboutiBio, Inc.:
iBio, Inc. (NYSEMKT:IBIO) owns the iBioLaunch™ platform, which is a transformative technology for developing and producing biologics by using transient gene expression in green plants that have not been modified. The company is involved in the development of a proprietary product that would be used for the treatment of systemic sclerosis, idiopathic pulmonary fibrosis and other fibrotic diseases by using its iBioLaunch platform. iBio, Inc. also offers the technology licenses to others and it provides collaborators the full support for turn-key implementation of company’s technology for protein therapeutics and vaccines.
UPDATE 1-Nurse who was Mali's second Ebola case dies -government
Wed Nov 12, 2014 4:34pm IST
(Adds details, background)
Nov 12 (Reuters) - A 25-year-old nurse who was Mali's second Ebola case has died, the government said in a statement on Wednesday.
The case involving the nurse at a private medical clinic in the capital, Bamako, is unrelated to Mali's first Ebola victim, a two-year-old girl from Guinea who died last month.
A group linked to the girl completed their 21-day quarantine on Tuesday but aid workers and the government now must track a new set of people who came in contact with the nurse and another man from Guinea who is believed to have infected the nurse when he travelled to and died in Mali with Ebola.
The government said that all necessary steps to identify people who had come into contact with the nurse, who died on Tuesday evening, had been taken.
It did not say how many people were being traced but said a private clinic and the nurse's home had been disinfected and sealed off.
The Pasteur Clinic, one of Bamako's best medical centres, was locked down by police on Tuesday night.
Mali, the sixth West African country to record a case of Ebola, shares an 800 km (500 mile) border with Guinea, which alongside Liberia and Sierra Leone, has been worst affected by an outbreak that has killed nearly 5,000 people this year. (Reporting by Joe Penney in Bamako; Writing and additional reporting by David Lewis; Editing by Dominic Evans)
Sentiment: Strong Buy